We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 23, 2020

Endoscopic Activity and Baseline Serum TNF-α Level Associated With Response to Ustekinumab in Patients With Crohn's Disease

Inflammatory Bowel Diseases

 

Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients
Inflamm. Bowel Dis. 2020 Oct 23;26(11)1669-1681, K Murate, K Maeda, M Nakamura, D Sugiyama, H Wada, T Yamamura, T Sawada, Y Mizutani, T Ishikawa, K Furukawa, E Ohno, T Honda, H Kawashima, R Miyahara, M Ishigami, H Nishikawa, M Fujishiro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading